TY - JOUR T1 - Regional and temporal variations affect the accuracy of variant-specific SARS-CoV-2 PCR assays JF - medRxiv DO - 10.1101/2021.11.08.21266083 SP - 2021.11.08.21266083 AU - Chamteut Oh AU - Palash Sashittal AU - Aijia Zhou AU - Leyi Wang AU - Mohammed El-Kebir AU - Thanh H. Nguyen Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/07/2021.11.08.21266083.abstract N2 - Monitoring the prevalence of SARS-CoV-2 variants is necessary to make informed public health decisions during the COVID-19 pandemic. PCR assays have received global attention, facilitating rapid understanding of variant dynamics because they are more accessible and scalable than genome sequencing. However, as PCR assays target only a few mutations, their accuracy could be compromised when these mutations are not exclusive to target variants. Here we show how to design variant-specific PCR assays with high sensitivity and specificity across different geographical regions by incorporating sequences deposited in the GISAID database. Furthermore, we demonstrate that several previously developed PCR assays have decreased accuracy outside their study areas. We introduce PRIMES, an algorithm that enables the design of reliable PCR assays, as demonstrated in our experiments to track dominant SARS-CoV-2 variants in local sewage samples. Our findings will contribute to improving PCR assays for SARS-CoV-2 variant surveillance.Importance Monitoring the introduction and prevalence of variants of concern (VOCs) and variants of interest (VOIs) in a community can help the local authorities make informed public health decisions. PCR assays can be designed to keep track of SARS-CoV-2 variants by measuring unique mutation markers that are exclusive to the target variants. However, the mutation markers can not be exclusive to the target variants depending on regional and temporal differences in variant dynamics. We introduce PRIMES, an algorithm that enables the design of reliable PCR assays for variant detection. Because PCR is more accessible, scalable, and robust to sewage samples over sequencing technology, our findings will contribute to improving global SARS-CoV-2 variant surveillance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Grainger College of Engineering and the JUMP-ARCHES program of OSF Healthcare in conjunction with the University of Illinois. Sequencing was funded in part by the Food and Drug Administration Veterinary Laboratory Investigation and Response Network (FOA PAR-17-141) under grant 1U18FD006673-01. M.E-K. acknowledges the National Science Foundation (grants: CCF-2027669 and CCF-2046488). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -